Medicare AdvantagePrior AuthMedium impact
Leuprolide Acetate Subcutaneous Products (Eligard and Vabrinty) (Revised)
Humana·Oncology, Urology·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage now requires prior authorization for Eligard and Vabrinty (leuprolide acetate) subcutaneous products used to treat prostate cancer. The policy covers all formulations (1, 3, 4, and 6-month versions) and requires members to have advanced prostate cancer or high risk of disease recurrence.
Action Required
Before January 1, 2026: Billing team must update prior authorization processes for all Eligard and Vabrinty (leuprolide acetate) subcutaneous products for Humana Medicare Advantage members. Verify patient has advanced prostate cancer or high risk of disease recurrence before administration. Visit www.humana.com/PAL for specific medical and procedural coding information. Claims will be denied without prior authorization.